Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Cash & Equivalents (2016 - 2026)

Spyre Therapeutics' Cash & Equivalents history spans 11 years, with the latest figure at $85.7 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 4.14% year-over-year to $85.7 million; the TTM value through Dec 2025 reached $85.7 million, down 4.14%, while the annual FY2025 figure was $85.7 million, 4.14% down from the prior year.
  • Cash & Equivalents reached $85.7 million in Q4 2025 per SYRE's latest filing, up from $63.2 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $235.4 million in Q2 2023 to a low of $14.6 million in Q1 2022.
  • Average Cash & Equivalents over 5 years is $77.1 million, with a median of $55.0 million recorded in 2025.
  • Peak YoY movement for Cash & Equivalents: tumbled 83.19% in 2021, then soared 545.67% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $15.1 million in 2021, then skyrocketed by 130.24% to $34.9 million in 2022, then skyrocketed by 441.82% to $188.9 million in 2023, then crashed by 52.66% to $89.4 million in 2024, then decreased by 4.14% to $85.7 million in 2025.
  • Per Business Quant, the three most recent readings for SYRE's Cash & Equivalents are $85.7 million (Q4 2025), $63.2 million (Q3 2025), and $81.7 million (Q2 2025).